Business Wire

Thales and Google Cloud Join Forces to Deliver Breakthrough Capability for Enterprises to Control Their Data in the Cloud

7.12.2020 14:00:00 EET | Business Wire | Press release

Share

Thales announced a new collaboration with Google Cloud that will accelerate the ability of enterprises to safely migrate sensitive data between public cloud, hybrid and private IT infrastructures. Together, the two companies will offer new capabilities that enable security teams to own and control their encryption keys while helping to fulfill heightened regulatory requirements amidst today’s highly-distributed workforce. Building on a multi-year history of innovation around a variety of cloud security initiatives, Thales and Google Cloud will now empower customers to leverage the full potential of Google Cloud technology for sensitive workloads while gaining the external key management needed to control and secure data across hybrid cloud IT environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201207005373/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

Securing the New IT Frontier: Hybrid Cloud

This collaboration marks a significant moment for organisations to finally seize full control of their data and encryption keys, especially as they pursue hybrid, multi-cloud strategies. Addressing both private and public cloud environments, Thales and Google Cloud will provide a turnkey solution that manages, brokers and stores encryption keys completely controlled by the customer, effectively enabling companies to move data assets to the cloud with confidence. As uncovered in the Thales 2020 Data Threat Report-Global Edition, this is increasingly becoming more critical as greater than half of the world’s corporate data – of which 48% is sensitive – is stored in the cloud.

“New capabilities are critical to cloud migration and security, especially with such accelerated growth in this area,” said Sunil Potti, VP and GM of Google Cloud Security. “True to our mission, we've forged this deeper relationship with Thales to further protect our customer’s most sensitive information. Companies of all shapes and sizes are dealing with an extremely fluid and dynamic business environment where even the best lines of defence are constantly being battle tested. Together with Thales, we acknowledge the current set of circumstances and remain vigilant to provide customers with the most advanced solutions that address today’s cybersecurity needs as well as those that are emerging on the horizon.”

This collaboration greatly simplifies the security of moving to multi-cloud, hybrid cloud, and edge-cloud environments – a journey more companies are making today to address the post-pandemic remote world. According to 451 Research, 62% of enterprises today are pursuing a hybrid IT strategy. In addition, by working with Thales to handle application and data security in the cloud, Google Cloud customers can now maintain strong data sovereignty with encryption key visibility and lifecycle management. Customers also can address heightened regulatory requirements stemming from recent data and privacy regulations.

“Our collaboration with Google Cloud truly embodies the technology leadership needed to place the control of data directly into the hands of our customers,” said Sebastien Cano, SVP for Cloud Protection & Licensing at Thales. “Companies no longer need to put their sensitive data in untrusted environments and relinquish control of their coveted encryption keys. It has become abundantly clear that an evolution in data protection is taking place at a global level as security professionals work together to build a shared-responsibility security model between enterprise customers and providers. With this joint innovation effort, we’re supporting organisations as they move to the cloud with confidence.”

Establishing a Foundation of Trust in the Cloud

To help organisations benefit from this enhanced level of control of keys and cloud data, Thales has integrated its CipherTrust Key Broker service with Google Cloud External Key Manager (EKM). The CipherTrust Key Broker for Google Cloud EKM is available on Thales’s Data Protection on Demand platform. By generating encryption keys using CipherTrust Key Broker, organisations can verify the origin and quality of the keys they are providing to the cloud provider, while maintaining the original version of the key outside of the Google Cloud environment. Organisations hold their master keys in a Thales Luna Cloud HSM, which acts as the trust anchor for the CipherTrust Key Broker solution. For more information download the CipherTrust Key Broker solution brief.

Industry insight and views on the latest data security trends can be found on the Thales blog.

Follow Thales on Twitter, LinkedIn, Facebook and YouTube .

About Thales

Thales (Euronext Paris: HO) is a global high technology leader investing in digital and “deep tech” innovations –connectivity, big data, artificial intelligence, cybersecurity and quantum technology – to build a future we can all trust, which is vital to the development of our societies. The company provides solutions, services and products that help its customers –businesses, organisations and states – in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.

With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a basis including Gemalto over 12 months).

PLEASE VISIT
Thales Group
Market page

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT
Thales, Media Relations

Market
Laura Bandiera
+33 (0)7 64 48 51 64
laura.bandiera@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye